RADIOLABELED BC8 (ANTI-CD45) ANTIBODY COMBINED WITH BUSULFAN AND CYCLOPHOSPHAMIDE AS TREATMENT FOR ACUTE MYELOGENOUS LEUKEMIA IN FIRST OR SECOND REMISSION OR UNTREATED FIRST RELAPSE FOLLOWED BY HLA-IDENTICAL RELATED MARROW TRANSPLANTATION


Phase 2
16 Years
55 Years
Not Enrolling
Both
Leukemia

Thank you

Trial Information

RADIOLABELED BC8 (ANTI-CD45) ANTIBODY COMBINED WITH BUSULFAN AND CYCLOPHOSPHAMIDE AS TREATMENT FOR ACUTE MYELOGENOUS LEUKEMIA IN FIRST OR SECOND REMISSION OR UNTREATED FIRST RELAPSE FOLLOWED BY HLA-IDENTICAL RELATED MARROW TRANSPLANTATION


OBJECTIVES: I. Determine the overall and disease-free survival and toxicity associated with
busulfan/cyclophosphamide (BU/CTX) plus 131I-labeled BC8 antibody (131I-BC8) followed by an
HLA-identical related marrow transplant in patients with acute myelogenous leukemia in first
or second remission or untreated first relapse. II. Study factors that may influence the
biodistribution of 131I-BC8 in this patient population, including marrow cellularity, the
level of antigen expression by leukemic cells (in relapsed patients), and the degree of
antigen saturation by antibody. III. Determine the efficacy of BU/CTX in patients in first
remission unable to receive radiolabeled antibody, e.g., patients who are HAMA-positive,
those not tolerating antibody test infusion, those with unfavorable antibody
biodistribution, or those for whom antibody is unavailable.

OUTLINE: Radioimmunotherapy plus 2-Drug Cytoreductive Chemotherapy followed by Bone Marrow
Transplantation with, as indicated, CNS Therapy. Iodine-131-labeled Monoclonal Antibody BC8
(anti-CD45), 131I-BC8; plus Busulfan, BU, NSC-750; Cyclophosphamide, CTX, NSC-26271;
followed by Allogeneic Bone Marrow, ABM; with, as indicated, Intrathecal Methotrexate, IT
MTX, NSC-740.

PROJECTED ACCRUAL: It is anticipated that 30 patients in first remission, 30 patients in
untreated first relapse, and 15 patients in second remission will be accrued over 3 years.

Inclusion Criteria


DISEASE CHARACTERISTICS: Acute myelogenous leukemia in first or second remission or
untreated first relapse Documented CD45 expression by leukemic cells required for patients
in relapse Phenotyping not required for patients in remission; such patients may have
leukemia previously documented to be CD45 negative Circulating blast count less than
10,000 (control with hydroxyurea or similar agent allowed) Genotypically or phenotypically
HLA-matched related marrow donor required No donors mismatched for 1 or more HLA antigens
No psychologic, physiologic, or medical contraindication to donation No high risk for
anesthesia because of age or medical problems No HIV seropositive donors

PATIENT CHARACTERISTICS: Age: 16 to 55 Performance status: Not specified Life expectancy:
Greater than 60 days Hematopoietic: Not applicable Hepatic: Bilirubin less than 1.5 mg/dl
No risk of developing veno-occlusive disease of the liver (i.e., current evidence of
hepatitis as manifested by SGOT greater than 1.5 x ULN) Renal: Creatinine less than 2.0
mg/dl Other: No HIV seropositivity No major infection

PRIOR CONCURRENT THERAPY: See Disease Characteristics No prior radiotherapy to maximally
tolerated levels for any normal organ

Type of Study:

Interventional

Study Design:

Primary Purpose: Treatment

Principal Investigator

John Pagel, MD, PhD

Investigator Role:

Study Chair

Investigator Affiliation:

Fred Hutchinson Cancer Research Center

Authority:

United States: Federal Government

Study ID:

832.00

NCT ID:

NCT00002554

Start Date:

November 1993

Completion Date:

December 1999

Related Keywords:

  • Leukemia
  • recurrent adult acute myeloid leukemia
  • adult acute myeloid leukemia in remission
  • Leukemia
  • Leukemia, Myeloid, Acute
  • Leukemia, Myeloid

Name

Location